Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Gilead Sciences

Legend Biotech

Novartis

The FDA has undertaken an investigation of T-cell malignancies in patients undergoing CAR T-cell therapy treatment. Therapies from NVS, BMY and GILD are under the spotlight.

CAR T-Cell Therapies Under FDA Watch on Reports of Malignancies

Investar Hhld

J. M. Smucker

Stocking stuffers are small, inexpensive presents that help to complete the holiday, so for this screen, the focus was on inexpensive stocks. Inexpensive means a low P/E multiple relative to the S&P 500 NYSEARCA: SPY, but it doesn't mean cheap.

3 stocking stuffers you can buy for yourself

Avidity Biosciences

Bristol Myers has agreed to pay Avidity $60 million in cash and will also purchase about $40 million of Avidity common stock at $7.88 a share.

Avidity Stock Soars on Collaboration Deal With Bristol Myers

Avidity Biosciences soared 35% in pre-market trading after announcing a global licensing and research collaboration with Bristol-Myers Squibb Co (NYSE:BMY).  The pact is focused on the discovery, development and commercialization of multiple cardiovascular targets with potential cumulative payments of up to $2.3 billion.

Avidity Biosciences leaps on Bristol-Myers research tie-up

Bristol-Myers Squibb Company is down 40%, while the market is up 20%. The reason is the collapse in its growth outlook created by patent cliffs. Despite some amazing growth in new drugs, Bristol's three super mega-blockbuster patent cliffs are creating zero-growth headwinds for the foreseeable future. Even without growth, Bristol-Myers is 28% undervalued, yielding the most in 15 years, and offers 50% upside return potential over the next 2 years.

Bristol-Myers Squibb Is A Great Buy, But These 5+% Yielding Bargains Are Better

Avidity Biosciences Inc. RNA said Tuesday it's expanding its cardiovascular collaboration with Bristol Myers Squibb Co. BMY in a deal that will see Avidity receive $100 million upfront with the potential to earn up to $2.2 billion in milestone payments. The news sent Avidity's stock up 21% in premarket trade.

Avidity's stock soars on news of expanded collaboration with Bristol Myers that includes potential to receive up to $2.2 billion in milestone payments

Realty Income Corp

Although the stock market whipsawed investors over the past few years, it showed its resilience by bouncing sharply higher after the pandemic collapse. As it has for more than a century, every double-digit decline by stocks is followed by a bull market.

3 Resilient Stocks with Massive Potential to Boost Your Wealth

Alibaba

Medical Properties Trust

Sibanye Stillwater

SPDR S&P 500 ETF Trust

VanEck Vectors Vietnam ETF

Walgreens

ZIM Integrated Shipping Services

Investors should consider selling stocks with negative catalysts and at risk of further decline. Taxable account holders may realize losses to offset this year's capital gains. Avoid Companies with high debt, falling demand, or higher operating losses ahead.

3 Tax-Loss Sell Alerts: These Stocks Likely To Fall By Even More

Bristol Myers Squibb's third quarter results indicate a more challenging recovery than previously communicated, leading to a downgrade in its medium-term outlook. The company's new product portfolio revenue is expected to face a delayed ramp, leading to the guidance downgrade. Bristol Myers Squibb also faces margin pressure while dealing with the loss of exclusivity with its drug Revlimid, further impacting its outlook.

Bristol Myers Squibb: A Bitter Pill But Still A Buy

Bristol-Myers Squibb Company is facing challenges due to the loss of exclusivity of its drug Revlimid and the need for new product growth. The company made a transformative deal with the acquisition of Celgene in 2019, but concerns about the growth profile remain. Despite efforts to boost performance, including acquisitions and sales growth, Bristol-Myers has experienced a decline in stock performance and lower sales and earnings.

Bristol-Myers Squibb: A Tough But Cheap Spot

Bristol Myers Squibb (BMY) and 2seventy bio, Inc.'s efforts to seek approval for the label expansion of Abecma for earlier lines of treatment face a roadblock.

Bristol Myers (BMY), TSVT Cell Therapy Abecma Faces Setback

Costco

McDonald's

Mondelez

Procter & Gamble

Southern Company

Based on the strong print of the major indices since late last month, the idea of deliberately targeting reliable stocks for a volatile market might seem overkill. In the past 30 days, the benchmark S&P 500 gained almost 6%.

Soothing Stocks: 7 Reliable Picks to Ease Your Market Jitters

Boeing

General Motors

U.S. equities began the Thanksgiving holiday-shortened trading week higher at midday after optimism about slowing inflation buoyed markets last week. The Dow, S&P 500, and Nasdaq all gained.

Midday Movers: Boeing and GM Advance, Bristol-Myers Squibb Declines

2Seventy Bio

Shares of Bristol-Myers Squibb (BMY) and partner 2seventy bio (TSVT) slumped after the two companies announced that the Food and Drug Administration (FDA) would not make a decision on expanded use for their blood cancer treatment, Abecma, next month as originally planned.

Bristol-Myers Squibb, 2seventy Bio Shares Fall as FDA Delays Decision on Cancer Drug

Bayer announced that it is halting a late-stage trial for asundexian, a high-profile candidate for cardiovascular disease. Bristol Myers Squibb and Johnson & Johnson are co-developing a therapy that belongs to the same class as asundexian.

Why Bristol Myers Squibb Stock Is Fading Today

Bristol-Myers Squibb (NYSE: BMY ) stock is falling on Monday after a couple of updates that are weighing on BMY shares today. The first bit of news worth noting are results from a clinical trial of Bayer's blood-thinning drug candidate asundexian.

Why Is Bristol-Myers Squibb (BMY) Stock Down Today?

Abecma, developed with 2seventy Bio, won't be approved for earlier treatments of a certain kind of blood cancer by a Dec. 16 deadline.

Bristol Myers Squibb Stock Falls After Drug Approval Delayed

Bristol-Myers Squibb Co (NYSE:BMY) shares fell almost 5% after the company announced that a Food and Drug Administration (FDA) decision on the use of its blood cancer therapy Abecma, developed with partner 2seventy bio, may be delayed. The companies said Monday that they have been informed by the FDA that a decision on their supplemental Biologics License Application (sBLA) for Abecma for earlier lines of triple-class exposed relapsed or refractory multiple myeloma (RRMM) will not be made by the Prescription Drug User Fee Act target action date of December 16, 2023.

Bristol-Meyers Squibb shares fall as FDA delays blood cancer therapy decision

Shares of Bristol Myers Squibb Co. BMY and 2seventy bio Inc. TSVT fell premarket on Monday after the companies said the U.S. Food and Drug Administration would miss its target date for potential approval of earlier use of a cancer therapy.

Bristol Myers Squibb, 2seventy bio shares fall as FDA delays action on cancer treatment

The U.S. Food and Drug Administration (FDA) will not make a decision on Bristol Myers Squibb and 2seventy bio's marketing application of their blood cancer therapy, Abecma, for earlier lines of treatment by Dec. 16.

US FDA delays decision on Bristol Myers-2seventy bio cancer therapy

PRINCETON, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BMY #2seventy--BMS and 2seventy bio Provide Update on U.S. FDA Review of sBLA for Abecma (idecabtagene vicleucel).

Bristol Myers Squibb and 2seventy bio Provide Update on U.S. FDA Review of sBLA for Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma

Whirlpool

As the third quarter 2023 earnings season ends, it's worth looking back to see which stocks may have been overlooked or mispriced on their results. Regardless of sector or industry, every earnings season has its share of misfits and heroes.

2 overlooked stocks that crushed earnings but traded lower

Bank of America

Cardinal Health

Kraft Heinz

PepsiCo

Walmart

2023 has been a much better year than 2022, as all major indices are higher. The tech-heavy Nasdaq is up a whopping 32.5%, while the venerable S&P 500 is up 15.36% and the Dow Jones Industrial just 3.5%, but it hasn't felt like a bull market, at least not yet.

7 Dividend Stocks To Buy For the Coming Bear Market

Bristol Myers Squibb is facing short-term pressure on financial results due to generic growth impacting its flagship drug Revlimid. BMY is actively investing in new drugs and companies to strengthen its position in fast-growing markets and create synergies with existing drugs. The company has lowered its revenue guidance for Revlimid in 2023 but expects to be back on a growth trajectory in 2025+ through drug approvals and the Mirati acquisition.

Bristol Myers Squibb: Bright Future Ahead

Bristol Myers' (BMY) repotrectinib, a tyrosine kinase inhibitor (???TKI???) targeting ROS1 oncogenic fusions, gets FDA?

News for Bristol-Myers Stock (BMY)